Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.22
SYK's Cash to Debt is ranked lower than
60% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. SYK: 1.22 )
Ranked among companies with meaningful Cash to Debt only.
SYK' s 10-Year Cash to Debt Range
Min: 0.04  Med: 1.86 Max: 164.16
Current: 1.22
0.04
164.16
Equity to Asset 0.50
SYK's Equity to Asset is ranked lower than
69% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 0.66 vs. SYK: 0.50 )
Ranked among companies with meaningful Equity to Asset only.
SYK' s 10-Year Equity to Asset Range
Min: 0.22  Med: 0.63 Max: 0.78
Current: 0.5
0.22
0.78
F-Score: 3
Z-Score: 4.55
M-Score: -2.81
WACC vs ROIC
11.54%
9.13%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 15.60
SYK's Operating margin (%) is ranked higher than
83% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 3.12 vs. SYK: 15.60 )
Ranked among companies with meaningful Operating margin (%) only.
SYK' s 10-Year Operating margin (%) Range
Min: -5.63  Med: 18.48 Max: 23.92
Current: 15.6
-5.63
23.92
Net-margin (%) 6.86
SYK's Net-margin (%) is ranked higher than
69% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 1.45 vs. SYK: 6.86 )
Ranked among companies with meaningful Net-margin (%) only.
SYK' s 10-Year Net-margin (%) Range
Min: 0.92  Med: 12.00 Max: 17.39
Current: 6.86
0.92
17.39
ROE (%) 7.67
SYK's ROE (%) is ranked higher than
62% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 2.94 vs. SYK: 7.67 )
Ranked among companies with meaningful ROE (%) only.
SYK' s 10-Year ROE (%) Range
Min: 2.89  Med: 20.76 Max: 28.97
Current: 7.67
2.89
28.97
ROA (%) 3.93
SYK's ROA (%) is ranked higher than
62% of the 324 Companies
in the Global Medical Devices industry.

( Industry Median: -0.62 vs. SYK: 3.93 )
Ranked among companies with meaningful ROA (%) only.
SYK' s 10-Year ROA (%) Range
Min: 0.71  Med: 12.15 Max: 15.38
Current: 3.93
0.71
15.38
ROC (Joel Greenblatt) (%) 64.30
SYK's ROC (Joel Greenblatt) (%) is ranked higher than
91% of the 318 Companies
in the Global Medical Devices industry.

( Industry Median: 3.55 vs. SYK: 64.30 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SYK' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 13.85  Med: 60.16 Max: 73.6
Current: 64.3
13.85
73.6
Revenue Growth (3Y)(%) 5.80
SYK's Revenue Growth (3Y)(%) is ranked higher than
59% of the 193 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. SYK: 5.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SYK' s 10-Year Revenue Growth (3Y)(%) Range
Min: 5.8  Med: 11.40 Max: 32.9
Current: 5.8
5.8
32.9
EBITDA Growth (3Y)(%) -5.70
SYK's EBITDA Growth (3Y)(%) is ranked lower than
60% of the 171 Companies
in the Global Medical Devices industry.

( Industry Median: 2.10 vs. SYK: -5.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SYK' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -9.6  Med: 13.70 Max: 59.4
Current: -5.7
-9.6
59.4
EPS Growth (3Y)(%) -26.90
SYK's EPS Growth (3Y)(%) is ranked lower than
78% of the 170 Companies
in the Global Medical Devices industry.

( Industry Median: -2.00 vs. SYK: -26.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SYK' s 10-Year EPS Growth (3Y)(%) Range
Min: -43  Med: 16.70 Max: 153
Current: -26.9
-43
153
» SYK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

SYK Guru Trades in Q2 2014

Mario Gabelli 20,100 sh (New)
Jim Simons 38,800 sh (New)
George Soros 1,678,108 sh (+52.75%)
Paul Tudor Jones 7,777 sh (+38.88%)
PRIMECAP Management 304,500 sh (unchged)
Vanguard Health Care Fund 1,433,500 sh (unchged)
Ray Dalio Sold Out
Joel Greenblatt Sold Out
Ken Fisher 3,320 sh (-2.64%)
Robert Olstein 98,000 sh (-5.77%)
Yacktman Fund 4,613,000 sh (-5.86%)
Donald Yacktman 10,178,928 sh (-12.19%)
Chuck Royce 92,000 sh (-12.21%)
Jeremy Grantham 2,047,202 sh (-17.21%)
Yacktman Focused Fund 3,830,000 sh (-20.21%)
» More
Q3 2014

SYK Guru Trades in Q3 2014

Dodge & Cox 4,170 sh (New)
Ray Dalio 10,341 sh (New)
Diamond Hill Capital 425,344 sh (New)
Paul Tudor Jones 80,548 sh (+935.72%)
Jim Simons 131,600 sh (+239.18%)
Ken Fisher 3,535 sh (+6.48%)
Jeremy Grantham 2,135,547 sh (+4.32%)
Robert Olstein 98,000 sh (unchged)
PRIMECAP Management 304,500 sh (unchged)
Vanguard Health Care Fund 1,433,500 sh (unchged)
Mario Gabelli 20,100 sh (unchged)
Yacktman Fund 4,400,000 sh (-4.62%)
Donald Yacktman 9,596,895 sh (-5.72%)
Yacktman Focused Fund 3,500,000 sh (-8.62%)
George Soros 1,368,566 sh (-18.45%)
Chuck Royce 72,200 sh (-21.52%)
» More
Q4 2014

SYK Guru Trades in Q4 2014

Diamond Hill Capital 1,001,380 sh (+135.43%)
Ray Dalio 11,841 sh (+14.51%)
Jeremy Grantham 2,262,681 sh (+5.95%)
Vanguard Health Care Fund 1,433,500 sh (unchged)
PRIMECAP Management 304,500 sh (unchged)
Chuck Royce Sold Out
George Soros Sold Out
Mario Gabelli Sold Out
Jim Simons Sold Out
Ken Fisher 3,366 sh (-4.78%)
Dodge & Cox 3,360 sh (-19.42%)
Yacktman Fund 3,435,000 sh (-21.93%)
Yacktman Focused Fund 2,717,000 sh (-22.37%)
Donald Yacktman 7,334,707 sh (-23.57%)
Robert Olstein 73,000 sh (-25.51%)
Paul Tudor Jones 3,000 sh (-96.28%)
» More
Q1 2015

SYK Guru Trades in Q1 2015

Jana Partners 50,000 sh (New)
Joel Greenblatt 40,138 sh (New)
Eric Mindich 389,000 sh (New)
Steven Cohen 85,000 sh (New)
Jim Simons 245,500 sh (New)
Paul Tudor Jones 17,014 sh (+467.13%)
Ray Dalio 17,433 sh (+47.23%)
Jeremy Grantham 2,378,456 sh (+5.12%)
Robert Olstein 73,000 sh (unchged)
Vanguard Health Care Fund 1,433,500 sh (unchged)
Dodge & Cox 3,360 sh (unchged)
Louis Moore Bacon 75,000 sh (unchged)
Ken Fisher 3,320 sh (-1.37%)
Diamond Hill Capital 986,354 sh (-1.50%)
PRIMECAP Management 295,500 sh (-2.96%)
Yacktman Fund 3,050,000 sh (-11.21%)
Donald Yacktman 6,365,465 sh (-13.21%)
Yacktman Focused Fund 2,300,000 sh (-15.35%)
» More
» Details

Insider Trades

Latest Guru Trades with SYK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 54.76
SYK's P/E(ttm) is ranked lower than
79% of the 155 Companies
in the Global Medical Devices industry.

( Industry Median: 28.20 vs. SYK: 54.76 )
Ranked among companies with meaningful P/E(ttm) only.
SYK' s 10-Year P/E(ttm) Range
Min: 11.31  Med: 25.45 Max: 70.9
Current: 54.76
11.31
70.9
Forward P/E 17.48
SYK's Forward P/E is ranked higher than
67% of the 97 Companies
in the Global Medical Devices industry.

( Industry Median: 22.68 vs. SYK: 17.48 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 55.90
SYK's PE(NRI) is ranked lower than
79% of the 153 Companies
in the Global Medical Devices industry.

( Industry Median: 28.20 vs. SYK: 55.90 )
Ranked among companies with meaningful PE(NRI) only.
SYK' s 10-Year PE(NRI) Range
Min: 11.3  Med: 25.90 Max: 71.37
Current: 55.9
11.3
71.37
P/B 4.35
SYK's P/B is ranked lower than
64% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 3.23 vs. SYK: 4.35 )
Ranked among companies with meaningful P/B only.
SYK' s 10-Year P/B Range
Min: 2.19  Med: 3.38 Max: 7.77
Current: 4.35
2.19
7.77
P/S 3.77
SYK's P/S is ranked lower than
55% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 3.28 vs. SYK: 3.77 )
Ranked among companies with meaningful P/S only.
SYK' s 10-Year P/S Range
Min: 1.93  Med: 3.33 Max: 5.29
Current: 3.77
1.93
5.29
PFCF 20.98
SYK's PFCF is ranked higher than
70% of the 114 Companies
in the Global Medical Devices industry.

( Industry Median: 32.21 vs. SYK: 20.98 )
Ranked among companies with meaningful PFCF only.
SYK' s 10-Year PFCF Range
Min: 11.63  Med: 19.85 Max: 65.41
Current: 20.98
11.63
65.41
POCF 18.71
SYK's POCF is ranked higher than
61% of the 148 Companies
in the Global Medical Devices industry.

( Industry Median: 21.95 vs. SYK: 18.71 )
Ranked among companies with meaningful POCF only.
SYK' s 10-Year POCF Range
Min: 10.24  Med: 16.99 Max: 42.83
Current: 18.71
10.24
42.83
EV-to-EBIT 23.71
SYK's EV-to-EBIT is ranked lower than
54% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 22.01 vs. SYK: 23.71 )
Ranked among companies with meaningful EV-to-EBIT only.
SYK' s 10-Year EV-to-EBIT Range
Min: 6.8  Med: 15.10 Max: 35.3
Current: 23.71
6.8
35.3
Shiller P/E 32.90
SYK's Shiller P/E is ranked lower than
54% of the 95 Companies
in the Global Medical Devices industry.

( Industry Median: 31.07 vs. SYK: 32.90 )
Ranked among companies with meaningful Shiller P/E only.
SYK' s 10-Year Shiller P/E Range
Min: 15.99  Med: 25.73 Max: 71.18
Current: 32.9
15.99
71.18
Current Ratio 2.36
SYK's Current Ratio is ranked lower than
53% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 2.53 vs. SYK: 2.36 )
Ranked among companies with meaningful Current Ratio only.
SYK' s 10-Year Current Ratio Range
Min: 1.61  Med: 2.83 Max: 5.37
Current: 2.36
1.61
5.37
Quick Ratio 1.93
SYK's Quick Ratio is ranked lower than
51% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. SYK: 1.93 )
Ranked among companies with meaningful Quick Ratio only.
SYK' s 10-Year Quick Ratio Range
Min: 0.98  Med: 2.24 Max: 4.63
Current: 1.93
0.98
4.63
Days Inventory 172.71
SYK's Days Inventory is ranked lower than
65% of the 284 Companies
in the Global Medical Devices industry.

( Industry Median: 129.39 vs. SYK: 172.71 )
Ranked among companies with meaningful Days Inventory only.
SYK' s 10-Year Days Inventory Range
Min: 123.02  Med: 150.12 Max: 302.65
Current: 172.71
123.02
302.65
Days Sales Outstanding 56.95
SYK's Days Sales Outstanding is ranked higher than
67% of the 276 Companies
in the Global Medical Devices industry.

( Industry Median: 68.45 vs. SYK: 56.95 )
Ranked among companies with meaningful Days Sales Outstanding only.
SYK' s 10-Year Days Sales Outstanding Range
Min: 46.58  Med: 61.88 Max: 140.81
Current: 56.95
46.58
140.81

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.40
SYK's Dividend Yield is ranked lower than
55% of the 168 Companies
in the Global Medical Devices industry.

( Industry Median: 1.43 vs. SYK: 1.40 )
Ranked among companies with meaningful Dividend Yield only.
SYK' s 10-Year Dividend Yield Range
Min: 0.14  Med: 0.98 Max: 1.66
Current: 1.4
0.14
1.66
Dividend Payout 0.74
SYK's Dividend Payout is ranked lower than
86% of the 108 Companies
in the Global Medical Devices industry.

( Industry Median: 0.41 vs. SYK: 0.74 )
Ranked among companies with meaningful Dividend Payout only.
SYK' s 10-Year Dividend Payout Range
Min: 0.18  Med: 0.27 Max: 1.91
Current: 0.74
0.18
1.91
Dividend growth (3y) 18.70
SYK's Dividend growth (3y) is ranked higher than
81% of the 48 Companies
in the Global Medical Devices industry.

( Industry Median: 2.90 vs. SYK: 18.70 )
Ranked among companies with meaningful Dividend growth (3y) only.
SYK' s 10-Year Dividend growth (3y) Range
Min: 0  Med: 21.60 Max: 81.9
Current: 18.7
0
81.9
Yield on cost (5-Year) 8.22
SYK's Yield on cost (5-Year) is ranked higher than
97% of the 175 Companies
in the Global Medical Devices industry.

( Industry Median: 1.37 vs. SYK: 8.22 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
SYK' s 10-Year Yield on cost (5-Year) Range
Min: 0.83  Med: 5.84 Max: 9.89
Current: 8.22
0.83
9.89
Share Buyback Rate 0.60
SYK's Share Buyback Rate is ranked higher than
86% of the 183 Companies
in the Global Medical Devices industry.

( Industry Median: -3.70 vs. SYK: 0.60 )
Ranked among companies with meaningful Share Buyback Rate only.
SYK' s 10-Year Share Buyback Rate Range
Min: 2  Med: 0.50 Max: -3.2
Current: 0.6

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 77.48
SYK's Price/Net Current Asset Value is ranked lower than
97% of the 205 Companies
in the Global Medical Devices industry.

( Industry Median: 6.76 vs. SYK: 77.48 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
SYK' s 10-Year Price/Net Current Asset Value Range
Min: 4.45  Med: 10.38 Max: 152.98
Current: 77.48
4.45
152.98
Price/Tangible Book 16.09
SYK's Price/Tangible Book is ranked lower than
87% of the 262 Companies
in the Global Medical Devices industry.

( Industry Median: 4.56 vs. SYK: 16.09 )
Ranked among companies with meaningful Price/Tangible Book only.
SYK' s 10-Year Price/Tangible Book Range
Min: 2.87  Med: 6.49 Max: 632.38
Current: 16.09
2.87
632.38
Price/Projected FCF 1.78
SYK's Price/Projected FCF is ranked higher than
56% of the 112 Companies
in the Global Medical Devices industry.

( Industry Median: 1.95 vs. SYK: 1.78 )
Ranked among companies with meaningful Price/Projected FCF only.
SYK' s 10-Year Price/Projected FCF Range
Min: 0.92  Med: 1.72 Max: 112.25
Current: 1.78
0.92
112.25
Price/Median PS Value 1.13
SYK's Price/Median PS Value is ranked higher than
52% of the 264 Companies
in the Global Medical Devices industry.

( Industry Median: 1.16 vs. SYK: 1.13 )
Ranked among companies with meaningful Price/Median PS Value only.
SYK' s 10-Year Price/Median PS Value Range
Min: 0.62  Med: 1.09 Max: 1.76
Current: 1.13
0.62
1.76
Price/Graham Number 6.23
SYK's Price/Graham Number is ranked lower than
83% of the 138 Companies
in the Global Medical Devices industry.

( Industry Median: 2.43 vs. SYK: 6.23 )
Ranked among companies with meaningful Price/Graham Number only.
SYK' s 10-Year Price/Graham Number Range
Min: 1.23  Med: 3.00 Max: 36.14
Current: 6.23
1.23
36.14
Earnings Yield (Greenblatt) (%) 4.28
SYK's Earnings Yield (Greenblatt) (%) is ranked higher than
73% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 0.20 vs. SYK: 4.28 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SYK' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 2.8  Med: 6.60 Max: 14.6
Current: 4.28
2.8
14.6
Forward Rate of Return (Yacktman) (%) -4.30
SYK's Forward Rate of Return (Yacktman) (%) is ranked lower than
65% of the 98 Companies
in the Global Medical Devices industry.

( Industry Median: 4.08 vs. SYK: -4.30 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
SYK' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -4.9  Med: 16.10 Max: 29.3
Current: -4.3
-4.9
29.3

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SMA, ZMH, STJ, EW » details
Traded in other countries:SYK.Germany, SYK.Switzerland, 0R2S.UK,
Stryker Corporation was incorporated in Michigan in 1946. It is a medical technology company. The Company offers medical technologies, including reconstructive, medical and surgical, and neurotechnology and spine products. Its business segments are Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics products consist of implants used in hip and knee joint replacements and trauma and extremities surgeries. The Company supports surgeons with the technology and services needed as the company develops new surgical techniques. The MedSurg products include surgical equipment and surgical navigation systems (Instruments); endoscopic and communications systems (Endoscopy); patient handling and emergency medical equipment (Medical); and reprocessed and remanufactured medical devices (Sustainability) as well as other medical device products used in a variety of medical specialties. The Neurotechnology and Spine products include both neurosurgical and neurovascular devices. Its neurotechnology offering includes products used for minimally invasive endovascular techniques; a comprehensive line of products for traditional brain and open skull base surgical procedures; orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. It also develops, manufacture and market spinal implant products including cervical, thoracolumbar and interbody systems used in spinal injury, deformity and degenerative therapies. The Company's competitors include Zimmer Holdings, Inc. (Zimmer), DePuy Synthes Company, a subsidiary of Johnson & Johnson, Biomet, Inc.,Smith & Nephew plc (Smith & Nephew), Medtronic, including Covidien. The Company's businesses are subject to varying degrees of governmental regulation in the countries in which the company operates and the general trend is toward increasingly stringent regulation.
» More Articles for SYK

Headlines

Articles On GuruFocus.com
Weekly 52-Week Highs Highlight: HUM, EBAY, SYK, FRCPRD Jun 02 2015 
Hill-Rom Q2 Earnings Beat Market Estimates May 09 2015 
Weekly Insider Sells Highlight: ADP, KMX, SYK, DVA Jan 05 2015 
Medovex Is A Strong Buy Dec 29 2014 
Diamond Hill Adds Two Companies to Portfolio in Third Quarter Dec 11 2014 
Medical Technology Company Offers Investment Opportunity Sep 25 2014 
Pain Relief and Profits Jul 27 2014 
Companies That Give Shareholders a Raise Feb 14 2014 
Ken Fisher’s Top Increases of the Fourth Quarter Jan 15 2014 
Stocks with the Greatest Net Guru Buying in Q2 Sep 09 2013 

More From Other Websites
New AHA Guidelines For The Early Management And Treatment Of Stroke Will Change The Standard Of Care... Jul 01 2015
Stryker Prepares to Extend Its Rally Jun 25 2015
America's top states for innovation in 2015 Jun 24 2015
Stryker to Host Conference Call on July 23, 2015 Jun 22 2015
Stryker to Host Conference Call on July 23, 2015 Jun 22 2015
3 Healthcare Stocks For A Growing Global Middle Class Jun 22 2015
curasan and Stryker overcome commercial differences Jun 22 2015
Stryker Orthopaedics Settlement Program Reaches Milestone - - 95% of Registered Eligible U.S.... Jun 12 2015
Stryker Orthopaedics Settlement Program Reaches Milestone - - 95% of Registered Eligible U.S.... Jun 12 2015
Is Stryker Corporation (SYK) Worth Adding to Your Portfolio? - Analyst Blog Jun 05 2015
Stryker's Bone Adhesive Technology to be Used by Launchpad - Analyst Blog Jun 02 2015
Weekly 52-Week Highs Highlight: HUM, EBAY, SYK, FRCPRD Jun 02 2015
LaunchPad Medical Executes Definitive License Agreement with Stryker for Novel Bone Adhesive... Jun 01 2015
Kevin Lobo, Stryker Chairman & CEO, on robotics, European opportunity and currency headwinds Jun 01 2015
Top Healthcare, Medical Equipment Stocks of 2015 May 27 2015
Will Healthcare and Biotech Propel Stocks Higher? May 19 2015
Stryker to Participate in Jefferies 2015 Healthcare Conference May 15 2015
Stryker to Participate in Jefferies 2015 Healthcare Conference May 15 2015
Coverage initiated on Stryker by Northland Capital May 14 2015
Osiris Therapeutics Q1 Earnings & Revenues Grow Y/Y - Analyst Blog May 11 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK